1. Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment
   Herman J. Woerdenbag et al, 2023, Cancers CrossRef
2. Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data?
   Catherine J. E. Ingram et al, 2021, The Pharmacogenomics Journal CrossRef
3. Multiplex analysis of genetic polymorphisms within UGT1A9, a gene involved in phase II of Δ9-THC metabolism
   Julia Sophie Schneider et al, 2019, International Journal of Legal Medicine CrossRef
4. Nanoparticle-mediated therapeutic management in cholangiocarcinoma drug targeting: Current progress and future prospects
   Chunkang Liu et al, 2023, Biomedicine & Pharmacotherapy CrossRef
5. The inhibition of UDP-glucuronosyltransferases (UGTs) by tetraiodothyronine (T4) and triiodothyronine (T3)
   Da-Wei Chen et al, 2018, Xenobiotica CrossRef
6. Cannabis Pharmacogenomics: A Path to Personalized Medicine
   Mariana Babayeva et al, 2023, Current Issues in Molecular Biology CrossRef
7. Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
   Liuting Yang et al, 2018, BMC Gastroenterology CrossRef
8. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms
   Akitomo Yokokawa et al, 2021, European Journal of Drug Metabolism and Pharmacokinetics CrossRef
9. Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir
   Parul Patel et al, 2020, Journal of Antimicrobial Chemotherapy CrossRef
10. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation
    Kouji Tagawa et al, 2023, Toxicology Mechanisms and Methods CrossRef